CNTX
MaterialsContext Therapeutics Inc
$2.41-0.03 (-1.23%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving CNTX Today?
No stock-specific AI insight has been generated for CNTX yet. Check back soon — insights are generated from recent news analysis.
Fundamentals
Market Cap$221M
P/E Ratio—
EPS—
Dividend Yield—
Dividend / Share—
ROE—
Profit Margin—
Debt / Equity—
Trading
Volume506K
Avg Volume (10D)—
Shares Outstanding91.9M
CNTX News
20 articles- Context Therapeutics Reports First Quarter 2026 Operating and Financial ResultsYahoo Finance·May 6, 2026
- Positive Signs As Multiple Insiders Buy Context Therapeutics StockYahoo Finance·Apr 27, 2026
- Context Therapeutics Announces CTIM-76 Receives FDA Fast Track Designation for the Treatment of Platinum-Resistant Ovarian CancerYahoo Finance·Apr 2, 2026
- Context Therapeutics Reports Full Year 2025 Operating and Financial ResultsYahoo Finance·Mar 23, 2026
- Context Therapeutics Announces Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2026Yahoo Finance·Mar 19, 2026
- Context Therapeutics Outlines Post-ADC T-Cell Engager Strategy, Teases Q2 Claudin 6 DataMarketbeat·Mar 14, 2026
- Context Therapeutics CEO Teases Q2 Claudin 6 Data, Nectin-4 Clinic Entry at TD Cowen ConferenceMarketbeat·Mar 8, 2026
- Context Therapeutics to Participate in Upcoming Investor ConferencesYahoo Finance·Feb 9, 2026
- Here's Why We're Not Too Worried About Context Therapeutics' (NASDAQ:CNTX) Cash Burn SituationYahoo Finance·Feb 5, 2026
- Context Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Yahoo Finance·Jan 16, 2026
- BioAtla Inc (BCAB) Q3 2025 Earnings Call Highlights: Strategic Partnerships and Promising Trial ...Yahoo Finance·Nov 14, 2025
- BioAtla Reports Third Quarter 2025 Financial Results and Highlights Recent ProgressYahoo Finance·Nov 13, 2025
- Context Therapeutics Highlights CT-95 and CT-202 Programs at 2025 SITC Annual MeetingYahoo Finance·Nov 7, 2025
- Context Therapeutics Reports Third Quarter 2025 Operating and Financial ResultsYahoo Finance·Nov 5, 2025
- Institutions profited after Context Therapeutics Inc.'s (NASDAQ:CNTX) market cap rose US$14m last week but private equity firms profited the mostYahoo Finance·Oct 8, 2025
- Context Therapeutics Announces Poster Presentations at the Society for Immunotherapy of Cancer’s (SITC) 40th Annual MeetingYahoo Finance·Oct 6, 2025
- Context Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)Yahoo Finance·Oct 3, 2025
- Is Context Therapeutics (NASDAQ:CNTX) In A Good Position To Invest In Growth?Yahoo Finance·Aug 29, 2025
- Context Therapeutics Reports Second Quarter 2025 Operating and Financial ResultsYahoo Finance·Aug 6, 2025
- Context Therapeutics Presents CTIM-76 Phase 1 Trial in Progress at ASCO 2025Yahoo Finance·Jul 25, 2025
All 20 articles loaded
Price Data
Open$2.34
Previous Close$2.44
Day High$2.45
Day Low$2.31
52 Week High—
52 Week Low—
Fundamentals
Market Cap$221M
P/E Ratio—
EPS—
Dividend Yield—
Dividend / Share—
ROE—
Profit Margin—
Debt / Equity—
Trading
Volume506K
Avg Volume (10D)—
Shares Outstanding91.9M
About Context Therapeutics Inc
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.
MaterialsPHARMACEUTICAL PREPARATIONS
Company Details
Security TypeStock
ExchangeNASDAQ
Currency—
Round Lot—
SICPHARMACEUTICAL PREPARATIONS
CIK—
Composite FIGI—
Share Class FIGI—